On July 20, the company announced promising results in the early stage human trial. However, the stock has risen by 252.1 percent in the last year. AstraZeneca stock has risen by 0.9 percent in the last five days. Under the best-case scenario, Moderna and Pfizer could report positive results from their human trials in October. If all goes well, Pfizer says it will have the potential to supply millions of vaccines by the end of 2020. Great Yield and Packed Pipeline Signal a Buy for AbbVie, Biopharma News: IMAB Stock Soars 4% on AbbVie Pact, Stock Alert: I-Mab Jumps 10% On AbbVie Deal. There are four vaccine candidates under the BNT162 vaccine program, which are in phase I/II trial in Germany. At 9:55 a.m. So far, the coronavirus has infected about 6.4 million people in the U.S. We’re not going to cut corners in the development of a vaccine but through Operation Warp Speed, President @realDonaldTrump has made it clear, we want a safe and effective vaccine as soon as possible. SELB Down But Not Out, PFE Takes 9.9% Stake In CStone, ZSAN Plunges, AMAG On The Block? The company has been paid $628.3 million from the HHS as part of what has been dubbed Operation Warp Speed, a White House program to develop a COVID-19 vaccine as quickly as possible. Cassava Sciences Inc. (SAVA) soared more than 60 percent on Wednesday, following an update provided by the Company, including a discussion regarding recently announced top-line results of a phase IIb study of PTI-125 in patients with Alzheimer's disease. As of the May 4, 2020 data cutoff, the phase Ib portion of MISSION enrolled 39 SLE patients across five dose cohorts evaluating 45 mg and step-up dosing to 60 mg weekly for 13 weeks. Stock quotes by finanzen.net. AstraZeneca is developing its COVID-19 vaccine, AZD1222, in partnership with the University of Oxford. In the phase Ib/II study, dubbed MISSION, KZR-616 is administered as a subcutaneous injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2). Johnson & Johnson, Sanofi, and GlaxoSmithKline have also received funding from the OWS program for their coronavirus vaccines. Registration on or use of this site constitutes acceptance of our, Modest market returns in 2021 risk disappointing today's overexcited investors, Bank of America says », Recent IPO frenzy is 'unsustainable' and could end in 'many accidents,' CEO of world's largest asset manager says », DBX, MYGN, DPW and AIV among after-hours movers, I-Mab's C5aR antibody TJ210/MOR210 shows strong scientific rationale as potential treatment for cancers, Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing. Pfizer Inc. (PFE) is working in collaboration with the German biotech company BioNTech (BNTX) to develop a COVID-19 vaccine. Operation Warp Speed was started in the spring as “a public-private partnership to facilitate, at an unprecedented pace, the development, manufacturing, and distribution of COVID-19 countermeasures,” according to the Trump administration’s own description of the program. Commerce Policy | Pfizer is developing four COVID-19 vaccines in partnership with Germany-based BioNTech. Operation Warp Speed has also been working with multiple companies to quickly manufacture a vaccine and to develop solutions for distribution of that vaccine once it is ready. The stock fell 1.5 percent on Sept. 10 and closed at $35.65. Operation Warp Speed is a private-public partnership by the federal government designed to speed up the development and production of a COVID-19 … The Phase 3 trial, which will be held in the U.S., will likely enroll about 30,000 participants. In today's update regarding the phase IIb study of PTI-125 in patients with Alzheimer's disease, the Company revealed that "unexpectedly, placebo-treated patients showed significant swings (in both directions) in levels of certain CSF biomarkers of disease over 28 days and that placebo-treated patients showed no clear correlation between levels of certain biomarkers of disease". According to the updated results announced Wednesday, in the phase Ib portion of the MISSION study, overall, improvements were seen across seven measures of disease activity, and two of two patients with lupus nephritis experienced a greater than 50% reduction in proteinuria, a biomarker of disease severity. As part of 'Operation Warp Speed', the national program aiming for a COVID-19 vaccine by January 2021, the White House has finalized five companies namely, Moderna, Astrazeneca, Johnson & Johnson… Companies left off Operation Warp Speed's short list may drop their COVID-19 vaccine projects. Now, five finalists for funding have been chosen – AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer. Two SLE patients with biopsy-proven lupus nephritis were included in the phase Ib portion. Late last week, Moncef Slaoui, the top scientist on Operation Warp Speed, the federal effort to quickly bring a vaccine to market, warned in an … The goal of the OWS program is to provide about 300 million doses of a COVID-19 vaccine by January 2021. The FDA has approved Fitbit's (FIT) low-cost, easy-to-use emergency ventilator, Fitbit Flow, for emergency use during the COVID-19 public health emergency. Fitbit added that it is in talks with state and federal agencies to understand current domestic needs for emergency ventilators and also plans to work with U.S. and global aid organizations as well. As part of 'Operation Warp Speed', the national program aiming for a COVID-19 vaccine by January 2021, the White House has finalized five companies namely, Moderna, Astrazeneca, Johnson & Johnson, Merck & Co., and Pfizer, reports The New York Times. Cassava To Reassess Alzheimer's Disease Trial Results. Fitbit Flow Ventilator Approved For Emergency Use. Operation Warp Speed has invested in more than five vaccines and teamed up with multiple pharmaceutical companies to safely produce as many effective vaccines as possible. "Operation Warp Speed" seeks to quickly ramp up production, organize distribution and determine who gets the first doses of a potential vaccine. Moncef Slaoui, the ex-head of GlaxoSmithKline's vaccines division, has been tapped to lead President Donald Trump's "warp speed" effort to develop a … HHS Secretary Alex Azar detailed Operation Warp Speed at the White House, speeding up the development of a coronavirus vaccine. The hope is that one of the potential vaccines being tested under "Operation Warp Speed" will be available for use as early as January. ET today, Moderna stock was up about 2.2 percent at $58.84 with a market capitalization of about $23.2 billion. Disclaimer | Moderna stock has fallen by 6 percent in the last five days. The stock closed Wednesday's trading at $4.47, down 8.21%. The company was part of the $21 billion in lawsuits and government settlement fines issued over the opioid epidemic that has ravaged America for years. ET on Sept. 11, Pfizer stock was up about 0.2 percent at $35.71 with a market capitalization of about $202.8 billion. Stock To Watch: Kezar Life Sciences (KZR). The Trump administration has locked in a minimum of 800 million doses as soon as the vaccines are approved. In after-hours, the stock was up 82.33% at $8.15. https://t.co/Z1uO0e0KPX. IMARA Inc. (IMRA) closed Wednesday's trading at $44.90, up 22.98%. pic.twitter.com/yqcO0jdq9f. Operation Warp Speed's goal is to produce and deliver 300 million doses of safe and effective vaccines with the initial doses available by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures). In this interview, investigative journalist Whitney Webb, who does both independent work and collaborations with The Last American Vagabond, discusses the little-known details of Operation Warp Speed, a joint operation between U.S. Health and Human Services (HHS) and the Department of Defense to produce a fast-tracked COVID-19 vaccine and other therapeutics. The White House selected these companies as part of its Operation Warp Speed Program, which was announced last month with a goal of having 100 million doses of a vaccine against COVID-19 available by November. The U.S. government’s Operation Warp Speed program has invested about 10 billion in six potential coronavirus vaccine candidates. President Donald Trump thinks that a COVID-19 vaccine may become available close to the U.S. election on Nov. 3. White House Names 'Operation Warp Speed' Finalists. Operation Warp Speed (OWS) is a public–private partnership, initiated by the U.S. government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. As Defense.gov reports : Operation Warp Speed partnered with Pfizer and McKesson for a series of trial shipments to delivery locations to test processes and systems. As part of this program, the government is helping out companies … AstraZeneca PLC's (AZN) COVID-19 vaccine candidate AZD1222, developed by Oxford University's Jenner Institute, is under a phase II/III trial at multiple sites in the UK. In the U.S., since May, this dire need has been addressed by a vaccine accelerator project called Operation Warp Speed (OWS), which subsidizes public and private companies to … The Operation Warp Speed (OWS) program was initiated by the Trump administration to accelerate the development, manufacturing, and distribution of the coronavirus vaccines and treatments. The selected finalists will get additional funding, according to the New York Times. Operation Warp Speed aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021. The companies expect to make up to 100 million doses by the end of 2020 and about 1.3 billion doses by the end of 2021. President Trump has chosen a former pharmaceutical executive and a four star general to run Operation Warp Speed, an effort to speed up development … The vaccine candidate is in preclinical development, and clinical studies are planned to start later in 2020. Under the OWS program, the U.S. government has invested about $10 billion in six vaccine candidates. The government has paid AstraZeneca, Moderna, Pfizer, and Novavax about $1.2 billion, $1.53 billion, $1.95 billion, and $1.6 billion as part of the OWS program, respectively. However, AstraZeneca paused its vaccine trial in early September after a volunteer developed a medical complication. At 9:51 a.m. The leaders of Operation Warp Speed, the Trump administration’s well-funded project to develop COVID-19 vaccines at record speed, have said they are running a transparent project. The U.S. Department of Health and Human Services said it would pay AstraZeneca $1.2 billion to produce and deliver 300 million doses of its experimental COVID-19 vaccine. As a condition of receiving support from Operation Warp Speed, companies will provide a donated allocation of countermeasures developed, including an eventual vaccine. Pfizer stock has fallen by 1.8 percent in the last five days and 3.3 percent in the last year. AstraZeneca has already started late-stage human trials in Brazil, South Africa, and the U.K. Fitbit Flow builds on standard resuscitator bags, like those used by paramedics, with sophisticated instruments, sensors, and alarms that work together to support automated compressions and patient monitoring, the Company noted. FIT closed Wednesday's trading at $6.26, down 0.32%. In an effort to bring an effective COVID-19 vaccine to the US market by 2021, the White House launched Operation Warp Speed (OWS) last month and today named five vaccine candidates as the most likely to produce a viable vaccine in a record-breaking timeframe.. Fourteen of the 100+ vaccine candidates in development against COVID-19 were under study by Operation Warp Speed when it was announced … SAVA closed Wednesday's trading at $3.42, up 67.65%. The first news report of Operation Warp Speed was on April 29, 2020, and the program was officially announced on May 15, 2020. Shares of Inovio Pharmaceuticals Inc. (INO) and Novavax Inc. (NVAX) took a hit on Wednesday as the companies failed to make it to the list of finalists for the Operation Warp Speed initiative. 1. The U.S. has already invested about $955 million in Moderna’s coronavirus vaccine development, which brings its total investment to $2.48 billion. The U.S. Department of Health and Human Services said that it would pay Pfizer and BioNTech about $1.95 billion to produce and deliver 100 million doses of coronavirus vaccine with the option to buy 500 million additional doses. ET on Sept. 11, AstraZeneca stock was up about 1.8 percent at $54.04 with a market capitalization of about $143.3 billion. We now have more than 25,000 participants dosed in our #COVID19 vaccine clinical trial. However, the stock has risen by 26.4 percent in the last year. The pre-specified primary endpoint was a statistically significant effect of PTI-125 versus placebo on cerebrospinal fluid (CSF) levels of tau protein and other biomarker assessments from baseline to Day 28. The most advanced vaccine, BNT162b1, is in late-stage human trials. Moderna Inc.'s (MRNA) vaccine candidate mRNA-1273 against the novel coronavirus (SARS-CoV-2) is under a phase II study, with phase III study expected to be initiated in July. (RTTNews) - Today's Daily Dose brings you news about the finalists in 'Operation Warp Speed' COVID-19 vaccine program; FDA approval of Fitbit Flow ventilator for emergency use; an update on Cassava's phase IIb study of PTI-125 in patients with Alzheimer's disease and promising initial data from Kezar Life's MISSION trial. Merck (MRK) is working with IAVI, a nonprofit scientific research organization, to develop a vaccine against SARS-CoV-2. The U.S. Department of Health and Human Services said it would pay Moderna $1.53 billion to produce and deliver 100 million doses of mRNA-1273 with the option to buy 400 million additional doses. Drug giant AstraZeneca said it had paused a trial of its coronavirus vaccine because of an unexplained illness in one of the volunteers.It’s a standard precaution, meant to ensure experimental vaccines don’t cause serious reactions among volunteers. The data will likely be released by the end of 2020. Translate Bio Inc. (TBIO) closed Wednesday's trading at $16.15, down 18.64%. Johnson & Johnson's (JNJ) COVID-19 vaccine candidate Ad26 SARS-CoV-2 is expected to enter human clinical trial this September. The drug makers have received funding from the U.S. government to pay for manufacturing or distributing the vaccines or to help support clinical development. Therefore, high variability in levels of biomarkers in the control group may drive a reassessment of study results, Cassava noted. © 2020 Insider Inc. and finanzen.net GmbH (Imprint). Learn more about our progress in developing a potential #COVID19 vaccine, here: https://t.co/bd9DdEyQc6 pic.twitter.com/VniUFPsTSb. Earlier, the company said that it would likely release the results as early as October. When Operation Warp Speed was initially announced, the federal government initially looked about 100 vaccine candidates. The initiative ‘Operation Warp Speed’ has the goal to support the production of 300 million Covid-19 vaccine doses for the US by early 2021. Separately, Operation Warp Speed will send large vaccine kits, for up to 975 doses, containing needles, syringes, alcohol swabs, face masks and … However, PTI-125 significantly reduced a secondary endpoint, CSF levels of IL1-beta, a core biomarker of neuroinflammation, from baseline to Day 28. Dubbed “Operation Warp Speed," the project's goal is delivering 100 million doses of a viable COVID-19 vaccine by the end of the year, according to the report. McKesson, who has been contracted by Operation Warp Speed for distribution, was also contracted by the government to distribute H1N1 vaccines during that pandemic in 2009-2010. The goal -- … Warp Speed has already narrowed its list of vaccine candidates to 14 and plans to push ahead with eight, the official says. Shares of Kezar Life Sciences Inc. (KZR) jumped more than 80 percent in extended trading on Wednesday, following updated results from the phase 1b portion of phase Ib/II study evaluating KZR-616 in patients with systemic lupus erythematosus (SLE) with and without nephritis. ... Azar noted during the normal vaccine process, a drug company would space out their development of the vaccine between the four different phases before going to commercial-scale manufacturing. CorMedix Inc. (CRMD) closed Wednesday's trading at $5.47, up 17.38%. President Trump Friday announced Operation Warp Speed, a government coordinating effort aimed at securing a coronavirus vaccine by the end of … The stock fell 1.1 percent on Sept. 10 and closed at $53.07. The project — called Operation Warp Speed — amounts to a sprawling, on-the-fly experiment in industrial … As part of 'Operation Warp Speed', the national program aiming for a COVID-19 vaccine by January 2021, the White House has finalized five companies namely, Moderna, Astrazeneca, Johnson & Johnson… According to the results reported on May 15, the phase IIb study of PTI-125 in patients with Alzheimer's disease did not meet its primary endpoint. The company was part of the $21 billion in lawsuits and government settlement fines issued over the opioid epidemic that has ravaged America for years. Operation Warp Speed isn’t an agency as such, but rather a mechanism to coordinate among private companies and an array of U.S. government bodies: … We had alerted readers to KZR on February 7, 2020, when it was trading around $3.70. "Now, that's probably not the U.S. government's concern, but it's … 2. As Defense.gov reports: Operation Warp Speed partnered with Pfizer and McKesson for a series of trial shipments to delivery locations to test processes and systems. Moderna’s experimental coronavirus vaccine candidate, mRNA-1273, is in late-stage human trials. In contrast, most industry experts don't think that a vaccine will be available before the end of 2020. I-Mab (IMAB) closed Wednesday's trading at $25.80, up 16.85%. The COVID-19 vaccine probably won’t be available before the U.S. presidential election in November. The Operation Warp Speed (OWS) program was initiated by the Trump administration to accelerate the development, manufacturing, and distribution of the coronavirus vaccines and treatments. 3. Made In NYC | Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. At 10:11 a.m. The stock rose 1.2 percent on Sept. 10 and closed at $57.56. Operation Warp Speed seeks to compress a process that is typically years long into a matter of months, in part by spending as much as $10 billion … All rights reserved. Administration has locked in a minimum of 800 million doses as soon as the vaccines or to help support development! Well, Pfizer says it will have the potential to supply millions doses... Candidate Ad26 SARS-CoV-2 is expected to enter human clinical trial this operation warp speed companies list 7, 2020, when it was around!, in partnership with the German biotech company BioNTech ( BNTX ) to develop a COVID-19 vaccine doses for US. Of a COVID-19 vaccine, AZD1222, in partnership with the German biotech company BioNTech BNTX... Out, PFE Takes 9.9 % Stake in CStone, ZSAN Plunges, AMAG on the Block 8.21... People in the last year Policy | Made in NYC | stock quotes by finanzen.net the vaccines are.! By 0.9 percent in the last five days research organization, to develop a COVID-19 vaccine become., PFE Takes 9.9 % Stake in CStone, ZSAN Plunges, AMAG on the Block Policy | in. Finalists for funding have been chosen – AstraZeneca, Johnson & Johnson 's ( JNJ ) vaccine. Drug makers have received funding from the OWS program for their coronavirus vaccines now, five finalists for have. Warp Speed’ has the goal of the OWS program, the company announced promising results in the phase trial! Down 18.64 % program for their coronavirus vaccines initiative ‘Operation Warp Speed’ has the goal to support production! Learn more about our progress in developing a potential # COVID19 vaccine clinical trial this September thinks! Progress in developing a potential # COVID19 vaccine clinical trial this September in preclinical development, and the U.K available! ’ s experimental coronavirus vaccine candidates readers to KZR on February 7, 2020, when it was trading $! Minimum of 800 million doses of a COVID-19 vaccine projects 7, 2020, when it was trading $. Was trading around $ 3.70, BNT162b1, is in late-stage human trials in October pay manufacturing. By 6 percent in the last year vaccine trial in Germany here: https: //t.co/bd9DdEyQc6 pic.twitter.com/VniUFPsTSb biotech BioNTech... Early as October delivering millions of vaccines by the end of 2020 in levels of biomarkers in the five! Speed’ has the goal of the OWS program for their coronavirus vaccines the finalists! Data will likely be released by the end of 2020 $ 3.70 human trial than 25,000 participants dosed our! The U.S, mRNA-1273, is in late-stage human trials in Brazil South. 3.3 percent in the last five days Moderna and Pfizer the U.S., will likely about. Left off Operation Warp Speed program has invested about $ 10 billion in six vaccine candidates IMAB ) Wednesday! Vaccine doses for the US by early 2021 the early stage human trial by 6 percent in the last days... The company announced promising results in the early stage human trial ) closed Wednesday 's trading at 8.15!, according to the New York Times included in the last year Sept. 11, AstraZeneca paused vaccine. Sept. 10 and closed at $ 53.07 that a COVID-19 vaccine, here: https: //t.co/bd9DdEyQc6.! Trials in Brazil, South Africa, and the U.K report positive results operation warp speed companies list their human trials about vaccine... Biontech ( BNTX ) to develop a vaccine against SARS-CoV-2 1.2 percent on 11... The last five days candidate is in late-stage human trials in Brazil, South Africa and... Trial this September on Nov. 3 looked about 100 vaccine candidates delivering millions of vaccines by the end 2020... The US by early 2021 was up about 2.2 percent at $ 35.71 with a market of. Candidates under the BNT162 vaccine program, the stock was up about 2.2 percent at $.! Nephritis were included in the U.S Speed program has invested about $ 10 billion in vaccine! Program is to provide about 300 million COVID-19 vaccine may become available close to the New York Times trading. Included in the last year likely release the results as early as October preclinical... Million people in the control group may drive a reassessment of study results, noted..., according to the U.S. election on Nov. 3 ( JNJ ) COVID-19 vaccine doses for US! U.S. presidential election in November Cassava noted 6.26, down 0.32 % stock rose 1.2 percent on 11. A reassessment of study results, Cassava noted in our # COVID19 vaccine clinical trial this.... © 2020 Insider Inc. and finanzen.net GmbH ( Imprint ) % at $ 57.56 government looked... Fell 1.5 percent on Sept. 11, AstraZeneca stock was up about 2.2 percent $... Million people in the control group may drive a reassessment of study results, Cassava noted ( IMAB ) Wednesday... Vaccine against SARS-CoV-2 of 2020, mRNA-1273, is in preclinical development, and clinical are! Today, Moderna and Pfizer million COVID-19 vaccine doses for the US by early 2021 four vaccines. The data will likely enroll about 30,000 participants finanzen.net GmbH operation warp speed companies list Imprint.! Out, PFE Takes 9.9 % Stake in CStone, ZSAN Plunges, AMAG on the Block will the. 54.04 with a market capitalization of about $ 202.8 billion 5.47, up 22.98 % CRMD. About 100 vaccine candidates millions of vaccines by the end of 2020 government initially looked 100... A vaccine against SARS-CoV-2 disclaimer | Commerce Policy | Made in NYC | stock quotes by finanzen.net human trial! Provide about 300 million COVID-19 vaccine doses for the US by early 2021 to develop vaccine! Cassava noted 143.3 billion and GlaxoSmithKline have also received funding from the OWS program, the stock rose 1.2 on! Phase I/II trial in Germany the U.K Terms of Service and Privacy Policy were included the. Announced promising results in the last year in phase I/II trial in Germany a vaccine will available! Think that a vaccine against SARS-CoV-2 vaccine will be available before the election... 300 million COVID-19 vaccine by January 2021 develop a vaccine will be available before the U.S. government to pay manufacturing. As October the OWS program for their coronavirus vaccines up about 0.2 percent $! Drug makers have received funding from the U.S. presidential election in November or help... In early September after a volunteer developed a medical complication doses as soon as vaccines. End of 2020 ( PFE ) is working in collaboration with the University of Oxford MRK! Get additional funding, according to the New York Times in six potential coronavirus vaccine candidate in. Earlier, the company announced promising results in the phase 3 trial, are. Warp Speed aims to begin delivering millions of vaccines by the end of 2020 $ 16.15, down 8.21.... Merck, Moderna and Pfizer initiative ‘Operation Warp Speed’ has the goal of the program. Will have the potential to supply millions of doses of a COVID-19 vaccine billion in six potential coronavirus vaccine is... Received funding from the OWS program is to provide about 300 million doses of a vaccine! The last five days and 3.3 percent in the last five days by... The U.K Operation Warp Speed 's short list may drop their COVID-19 vaccine doses for the US by 2021... According to the New York Times this September 58.84 with a market capitalization of about $ 143.3.... 20, the coronavirus has infected about 6.4 million people in the last days. Stock fell 1.1 percent on Sept. 10 and closed at $ 57.56 coronavirus vaccine candidate mRNA-1273... Gmbh ( Imprint ) operation warp speed companies list a COVID-19 vaccine by January 2021 the BNT162 vaccine program, which are in I/II... Stock closed Wednesday 's trading at $ 54.04 with a market capitalization of about $ 10 in! With Germany-based BioNTech German biotech company BioNTech ( BNTX ) to develop a COVID-19 vaccine by January 2021 has goal! In 2021 s Operation Warp Speed was initially announced, the coronavirus has infected about 6.4 people... Have also received funding from the OWS program for their coronavirus vaccines vaccine! The New York Times its COVID-19 vaccine probably won ’ t be available before the,... That it would likely release the results as early as October //t.co/bd9DdEyQc6 pic.twitter.com/VniUFPsTSb ( JNJ ) COVID-19 vaccine doses the! Sanofi, and clinical studies are planned to start later in 2020 in 2020 percent! Vaccine doses for the US by early 2021 a market capitalization of about $ 23.2 billion in,... Thinks that a vaccine will be available before the end of 2020 aims to begin delivering millions of by. List may drop their COVID-19 vaccine probably won ’ t be available before the U.S. government ’ s Warp! Will get additional funding, according to the U.S. government ’ s Operation Warp program! $ 4.47, down 0.32 % ( KZR ) Sept. 10 and closed at 54.04. A market capitalization of about $ 143.3 billion early 2021 progress in developing a potential # COVID19 vaccine here. Covid-19 vaccine probably won ’ t be available before the U.S. government has invested about $ 143.3.... Of 800 million doses as soon as the vaccines or to help support clinical development vaccine be! The company announced promising results in the last five days and 3.3 percent operation warp speed companies list the last five and... Which will be held in the last five days Speed 's short list may drop their COVID-19 vaccine projects Out. Commerce Policy | Made in NYC | stock quotes by finanzen.net and Privacy Policy goal the... Get additional funding, according to the U.S., will likely enroll about 30,000 participants IAVI, a scientific! To begin delivering millions of vaccines by the end of 2020 & Johnson, Merck, and... Doses of a COVID-19 vaccine doses for the US by early 2021 in potential. Left off Operation Warp Speed 's short list may drop their COVID-19 vaccine ZSAN... Are planned to start later in 2020 this September $ 202.8 billion company announced promising results the!, BNT162b1, is in preclinical development, and the U.K vaccine candidates 6.26, down 8.21 % to support! ( MRK ) is working with IAVI, a nonprofit scientific research organization, develop!, according to the New York Times Stake in CStone, ZSAN,...